(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
, | ||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||
Large accelerated filer | ☐ | ☒ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company |
i | 2024 FORM 10-K |
Item 1. | |||
Item 1A. | |||
Item 1B. | |||
Item 1C. | Cybersecurity | ||
Item 2. | |||
Item 3. | |||
Item 4. | |||
Item 5. | |||
Item 6. | Reserved | ||
Item 7. | |||
Item 7A. | |||
Item 8. | |||
Item 9. | |||
Item 9A. | |||
Item 9B. | |||
Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | ||
Item 10. | |||
Item 11. | |||
Item 12. | |||
Item 13. | |||
Item 14. | |||
Item 15. | |||
Item 16. | |||
2 | 2024 FORM 10-K | FORWARD-LOOKING STATEMENTS |
3 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
4 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
5 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
6 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
7 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
8 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
9 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
10 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
11 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
12 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
13 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
14 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
15 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
16 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
17 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
18 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
19 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
20 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
21 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
22 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
23 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
24 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
25 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
26 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
27 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
28 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
29 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
30 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
31 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
32 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Retail Stores | Retail Stores | Retail Stores | |||||
Alabama | 10 | Louisiana | 11 | Ohio | 20 | ||
Alaska | 1 | Maine | 3 | Oklahoma | 6 | ||
Arizona | 15 | Maryland | 16 | Oregon | 8 | ||
Arkansas | 8 | Massachusetts | 10 | Pennsylvania | 25 | ||
California | 68 | Michigan | 20 | Rhode Island | 1 | ||
Colorado | 15 | Minnesota | 16 | South Carolina | 10 | ||
Connecticut | 6 | Mississippi | 5 | South Dakota | 2 | ||
Delaware | 2 | Missouri | 12 | Tennessee | 15 | ||
Florida | 46 | Montana | 4 | Texas | 58 | ||
Georgia | 23 | Nebraska | 5 | Utah | 7 | ||
Hawaii | 2 | Nevada | 6 | Vermont | 1 | ||
Idaho | 3 | New Hampshire | 4 | Virginia | 20 | ||
Illinois | 24 | New Jersey | 15 | Washington | 18 | ||
Indiana | 14 | New Mexico | 4 | West Virginia | 3 | ||
Iowa | 6 | New York | 21 | Wisconsin | 12 | ||
Kansas | 5 | North Carolina | 21 | Wyoming | 2 | ||
Kentucky | 9 | North Dakota | 2 | ||||
Total | 640 |
33 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
34 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Period | Total Number of Shares Purchased(1)(2) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3) | ||||
September 29, 2024 through October 26, 2024 | 205 | $14.65 | — | $348,071,000 | ||||
October 27, 2024 through November 23, 2024 | 1,530 | $12.34 | — | 348,071,000 | ||||
November 24, 2024 through December 28, 2024 | 891 | $19.84 | — | 348,071,000 | ||||
Total | 2,626 | $15.07 | — | $348,071,000 |
35 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
12/28/19 | 01/02/21 | 01/01/22 | 12/31/22 | 12/30/23 | 12/28/24 | |
Sleep Number Corporation | $100 | $165 | $154 | $52 | $30 | $31 |
S&P 400 Specialty Stores Index | $100 | $119 | $173 | $162 | $199 | $195 |
The Nasdaq Stock Market (U.S.) Index | $100 | $145 | $177 | $118 | $170 | $223 |
36 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
37 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
38 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
39 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||||||||
$ | % of Net Sales | $ | % of Net Sales | $ | % of Net Sales | ||||||
Net sales | $1,682.3 | 100.0% | $1,887.5 | 100.0 % | $2,114.3 | 100.0% | |||||
Cost of sales | 679.5 | 40.4% | 799.0 | 42.3 % | 912.0 | 43.1% | |||||
Gross profit | 1,002.8 | 59.6% | 1,088.5 | 57.7 % | 1,202.3 | 56.9% | |||||
Operating expenses: | |||||||||||
Sales and marketing | 766.6 | 45.6% | 847.4 | 44.9 % | 919.6 | 43.5% | |||||
General and administrative | 150.0 | 8.9% | 146.6 | 7.8 % | 153.3 | 7.2% | |||||
Research and development | 45.3 | 2.7% | 55.8 | 3.0 % | 61.5 | 2.9% | |||||
Restructuring costs | 18.1 | 1.1% | 15.7 | 0.8 % | — | —% | |||||
Total operating expenses | 979.9 | 58.2% | 1,065.6 | 56.5 % | 1,134.4 | 53.7% | |||||
Operating income | 22.9 | 1.4% | 22.9 | 1.2 % | 67.9 | 3.2% | |||||
Interest expense, net | 48.4 | 2.9% | 42.7 | 2.3 % | 19.0 | 0.9% | |||||
(Loss) income before income taxes | (25.5) | (1.5%) | (19.8) | (1.0 %) | 48.9 | 2.3% | |||||
Income tax (benefit) expense | (5.2) | (0.3%) | (4.5) | (0.2 %) | 12.3 | 0.6% | |||||
Net (loss) income | $(20.3) | (1.2%) | $(15.3) | (0.8 %) | $36.6 | 1.7% | |||||
Net (loss) income per share: | |||||||||||
Basic | $(0.90) | $(0.68) | $1.63 | ||||||||
Diluted | $(0.90) | $(0.68) | $1.60 | ||||||||
Weighted-average number of common shares: | |||||||||||
Basic | 22.6 | 22.4 | 22.4 | ||||||||
Diluted | 22.6 | 22.4 | 22.9 |
2024 | 2023 | 2022 | |||
Retail stores | 87.6% | 86.8% | 86.3% | ||
Online, phone, chat and other | 12.4% | 13.2% | 13.7% | ||
Total Company | 100.0% | 100.0% | 100.0% |
Net Sales Increase/(Decrease) | |||||
2024 | 2023 | 2022 | |||
Retail comparable-store sales(1) | (9%) | (12%) | (8%) | ||
Online, phone and chat(1) | (17%) | (15%) | 4% | ||
Total Retail comparable sales change(1) | (10%) | (12%) | (6%) | ||
Net opened/closed stores and other | (1%) | 1% | 3% | ||
Total Company | (11%) | (11%) | (3%) |
40 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Average sales per store ($ in thousands)(1) | $2,601 | $2,853 | $3,281 | ||
Average sales per square foot(1) | $841 | $926 | $1,081 | ||
Stores > $2 million in net sales(2) | 57% | 65% | 76% | ||
Stores > $3 million in net sales(2) | 18% | 24% | 36% | ||
Average revenue per smart bed unit – Total Retail(3) | $5,818 | $5,755 | $5,403 |
2024 | 2023 | 2022 | |||
Beginning of period | 672 | 670 | 648 | ||
Opened | 12 | 36 | 49 | ||
Closed | (44) | (34) | (27) | ||
End of period | 640 | 672 | 670 |
41 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
42 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | ||
Total cash provided by (used in): | |||
Operating activities | $27,143 | $(9,028) | |
Investing activities | (26,291) | (58,352) | |
Financing activities | (1,441) | 68,127 | |
Net (decrease) increase in cash and cash equivalents | $(589) | $747 |
43 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
44 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Year | ||||||
2024 | 2023 | 2022 | ||||
Net (loss) income | $(20,334) | $(15,287) | $36,610 | |||
Income tax (benefit) expense | (5,162) | (4,466) | 12,285 | |||
Interest expense | 48,368 | 42,695 | 18,985 | |||
Depreciation and amortization | 64,979 | 72,479 | 66,626 | |||
Stock-based compensation | 11,444 | 14,855 | 13,223 | |||
Restructuring costs(1) | 18,066 | 15,728 | — | |||
CEO transition/Proxy contest costs(2) | 998 | — | — | |||
Asset impairments | 1,220 | 672 | 295 | |||
Adjusted EBITDA | $119,579 | $126,676 | $148,024 |
Year | |||||
2024 | 2023 | 2022 | |||
Net cash provided by (used in) operating activities | $27,143 | $(9,028) | $36,138 | ||
Subtract: Purchases of property and equipment | (23,505) | (57,056) | (69,454) | ||
Free cash flow | $3,638 | $(66,084) | $(33,316) |
45 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Year | |||||
2024 | 2023 | 2022 | |||
Adjusted net operating profit after taxes (Adjusted NOPAT) | |||||
Operating income | $22,872 | $22,942 | $67,880 | ||
Add: Operating lease interest(1) | 26,775 | 27,777 | 25,912 | ||
Less: Income taxes(2) | (11,907) | (11,851) | (23,542) | ||
Adjusted NOPAT | $37,740 | $38,868 | $70,250 | ||
Average adjusted invested capital | |||||
Total deficit | $(451,586) | $(441,928) | $(438,177) | ||
Add: Long-term debt(3) | 546,841 | 539,819 | 460,020 | ||
Add: Operating lease obligations(4) | 389,508 | 433,154 | 436,412 | ||
Total adjusted invested capital at end of period | $484,763 | $531,045 | $458,255 | ||
Average adjusted invested capital(5) | $497,972 | $496,612 | $400,038 | ||
Adjusted return on invested capital (Adjusted ROIC) | 7.6% | 7.8% | 17.6% |
46 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Description | Judgments and Uncertainties | Effect if Actual Results Differ from Assumptions | ||
Stock-Based Compensation | ||||
The Company has stock-based compensation plans, which include non- qualified stock options and stock awards. See Note 1, Business and Summary of Significant Accounting Policies, and Note 8, Shareholders’ Deficit, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its stock-based compensation programs. | Option-pricing models and generally accepted valuation techniques require management to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the volatility of its stock price, future employee forfeiture rates and future employee stock option exercise behaviors. Changes in these assumptions can materially affect the fair value estimates or future earnings adjustments. Performance-based stock awards require management to make assumptions regarding the likelihood of achieving performance targets. | The Company does not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions it uses to determine stock-based compensation expense. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to changes in stock-based compensation expense that could be material. In addition, if actual results are not consistent with the assumptions used, the stock-based compensation expense reported in its financial statements may not be representative of the actual economic cost of the stock-based compensation. Finally, if the actual forfeiture rates, or the actual achievement of performance targets, are not consistent with the assumptions used, the Company could experience future earnings adjustments. A 10% change in its stock-based compensation expense for the year ended December 28, 2024, would have affected net loss by approximately $0.9 million in 2024. | ||
47 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Description | Judgments and Uncertainties | Effect if Actual Results Differ from Assumptions | ||
Warranty Liabilities | ||||
The Company provides a limited warranty on most of the products it sells. See Note 1, Business and Summary of Significant Accounting Policies, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its warranty program and liabilities. | The majority of its warranty claims are incurred within the first year. However, the Company’s warranty liability contains uncertainties because its warranty obligations cover an extended period of time. A revision of estimated claim rates or the projected cost of materials and freight associated with sending replacement parts to customers could have a material adverse effect on future results of operations. | The Company has not made any material changes in its warranty liability assessment methodology during the past three fiscal years. The Company does not believe there is a reasonable likelihood that there will be a material change in the estimates or assumptions it uses to calculate its warranty liability. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to losses or gains that could be material. A 10% change in its warranty liability at December 28, 2024, would have affected net loss by approximately $0.5 million in 2024. | ||
Revenue Recognition | ||||
Certain accounting estimates relating to revenue recognition contain uncertainty because they require management to make assumptions and to apply judgment regarding the effects of future events. See Note 1, Business and Summary of Significant Accounting Policies, and Note 9, Revenue Recognition, to the Notes to Consolidated Financial Statements, included in Item 8, Financial Statements and Supplementary Data, of this Annual Report on Form 10-K, for a complete discussion of its revenue recognition policies. | The Company’s estimates of sales returns contain uncertainties as actual sales return rates may vary from expected rates, resulting in adjustments to net sales in future periods. These adjustments could have an adverse effect on future results of operations. | The Company has not made any material changes in the accounting methodology used to establish its sales returns allowance during the past three fiscal years. The Company does not believe there is a reasonable likelihood that there will be a material change in the estimates or assumptions it uses to calculate its sales returns allowance. However, if actual results are not consistent with its estimates or assumptions, the Company may be exposed to additional losses or gains in future periods. A 10% change in its sales returns allowance at December 28, 2024 would have affected net loss by approximately $1.5 million in 2024. |
48 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
49 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
50 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
51 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ | $ | |
Accounts receivable, net of allowances of $ | |||
Inventories | |||
Prepaid expenses | |||
Other current assets | |||
Total current assets | |||
Non-current assets: | |||
Property and equipment, net | |||
Operating lease right-of-use assets | |||
Goodwill and intangible assets, net | |||
Deferred income taxes | |||
Other non-current assets | |||
Total assets | $ | $ | |
Liabilities and Shareholders’ Deficit | |||
Current liabilities: | |||
Borrowings under revolving credit facility | $ | $ | |
Accounts payable | |||
Customer prepayments | |||
Accrued sales returns | |||
Compensation and benefits | |||
Taxes and withholding | |||
Operating lease liabilities | |||
Other current liabilities | |||
Total current liabilities | |||
Non-current liabilities: | |||
Operating lease liabilities | |||
Other non-current liabilities | |||
Total liabilities | |||
Shareholders’ deficit: | |||
Undesignated preferred stock; outstanding | |||
Common stock, $ shares issued and outstanding, respectively | |||
Additional paid-in capital | |||
Accumulated deficit | ( | ( | |
Total shareholders’ deficit | ( | ( | |
Total liabilities and shareholders’ deficit | $ | $ |
52 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Net sales | $ | $ | $ | ||
Cost of sales | |||||
Gross profit | |||||
Operating expenses: | |||||
Sales and marketing | |||||
General and administrative | |||||
Research and development | |||||
Restructuring costs | |||||
Total operating expenses | |||||
Operating income | |||||
Interest expense, net | |||||
(Loss) income before income taxes | ( | ( | |||
Income tax (benefit) expense | ( | ( | |||
Net (loss) income | $( | $( | $ | ||
Basic net (loss) income per share: | |||||
Net (loss) income per share – basic | $( | $( | $ | ||
Weighted-average shares – basic | |||||
Diluted net (loss) income per share: | |||||
Net (loss) income per share – diluted | $( | $( | $ | ||
Weighted-average shares – diluted |
53 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Common Stock | Additional Paid-in Capital | Accumulated Deficit | |||||||
Shares | Amount | Total | |||||||
Balance at January 1, 2022 | $ | $ | $( | $( | |||||
Net income | — | — | — | ||||||
Exercise of common stock options | — | ||||||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | ( | ( | ||||
Balance at December 31, 2022 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Exercise of common stock options | — | — | |||||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | ( | |||||
Balance at December 30, 2023 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Exercise of common stock options | — | — | |||||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | — | ( | ||||
Balance at December 28, 2024 | $ | $ | $( | $( |
54 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Cash flows from operating activities: | |||||
Net (loss) income | $( | $( | $ | ||
Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||
Depreciation and amortization | |||||
Stock-based compensation | |||||
Net loss on disposals and impairments of assets | |||||
Deferred income taxes | ( | ( | ( | ||
Changes in operating assets and liabilities: | |||||
Accounts receivable | ( | ( | |||
Inventories | ( | ( | |||
Income taxes | ( | ||||
Prepaid expenses and other assets | ( | ( | |||
Accounts payable | ( | ( | ( | ||
Customer prepayments | ( | ( | ( | ||
Accrued compensation and benefits | ( | ( | |||
Other taxes and withholding | ( | ( | |||
Other accruals and liabilities | ( | ( | ( | ||
Net cash provided by (used in) operating activities | ( | ||||
Cash flows from investing activities: | |||||
Purchases of property and equipment | ( | ( | ( | ||
Proceeds from sales of property and equipment | |||||
Issuance of notes receivable | ( | ( | |||
Investment in non-marketable equity securities | ( | ||||
Net cash used in investing activities | ( | ( | ( | ||
Cash flows from financing activities: | |||||
Repurchases of common stock | ( | ( | ( | ||
Net (decrease) increase in short-term borrowings | ( | ||||
Proceeds from issuance of common stock | |||||
Debt issuance costs | ( | ( | |||
Net cash (used in) provided by financing activities | ( | ||||
Net (decrease) increase in cash and cash equivalents | ( | ( | |||
Cash and cash equivalents, at beginning of period | |||||
Cash and cash equivalents, at end of period | $ | $ | $ | ||
Supplemental Disclosure of Cash Flow Information | |||||
Income taxes paid, net of refunds | $ | $ | $ | ||
Interest paid | $ | $ | $ | ||
Purchases of property and equipment included in accounts payable | $ | $ | $ |
55 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
56 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Leasehold improvements | |
Furniture and equipment | |
Production machinery | |
Computer equipment and software |
57 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Balance at beginning of period | $ | $ | $ | ||
Additions charged to costs and expenses for current-year sales | |||||
Deductions from reserves | ( | ( | ( | ||
Change in liabilities for pre-existing warranties during the current year, including expirations | ( | ( | |||
Balance at end of period | $ | $ | $ |
58 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
59 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Cost of Sales | Sales & Marketing | |||
• | Costs associated with purchasing, manufacturing, shipping, handling and delivering the Company’s products to its retail stores and customers, including payroll and benefits; | • | Advertising, marketing and media production; | |
• | Marketing and selling materials such as brochures, videos, websites, customer mailings and in-store signage; | |||
• | Physical inventory losses, scrap and obsolescence; | • | Payroll and benefits for sales and customer service staff; | |
• | Related occupancy and depreciation expenses; | • | Store occupancy costs; | |
• | Costs associated with returns and exchanges; and | • | Store depreciation expense; | |
• | Estimated costs to service customer warranty claims. | • | Credit card processing fees; and | |
• | Promotional financing costs. | |||
G&A | R&D(1) | |||
• | Payroll and benefit costs for corporate employees, including information technology, legal, human resources, finance, sales and marketing administration, investor relations and risk management; | • | Internal labor and benefits related to research and development activities; | |
• | Outside consulting services related to research and development activities; and | |||
• | Occupancy costs of corporate facilities; | • | Testing equipment related to research and development | |
• | Depreciation related to corporate assets; | ___________________________ (1) Costs incurred in connection with R&D are charged to expense as incurred. | ||
• | Information hardware, software and maintenance; | |||
• | Insurance; | |||
• | Investor relations costs; and | |||
• | Other overhead costs. |
60 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
61 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
62 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
63 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
December 28, 2024 | December 30, 2023 | ||
Raw Materials | $ | $ | |
Work in Progress | |||
Finished goods | |||
$ | $ |
64 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
December 28, 2024 | December 30, 2023 | ||
Finished beds, including deliveries in-transit to those customers who have utilized home delivery services | $ | $ | |
Finished components that were ready for assembly for the completion of beds | |||
Retail accessories | |||
$ | $ |
December 28, 2024 | December 30, 2023 | ||
Leasehold improvements | $ | $ | |
Furniture and equipment | |||
Production machinery, computer equipment and software | |||
Construction in progress | |||
Less: Accumulated depreciation and amortization | ( | ( | |
$ | $ |
December 28, 2024 | December 30, 2023 | ||||||
Gross Carrying Amount | Accumulated Amortization | Gross Carrying Amount | Accumulated Amortization | ||||
Developed technologies | $ | $ | $ | $ | |||
Patents | |||||||
$ | $ | $ | $ |
65 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2025 | $ |
2026 | |
2027 | |
2028 | |
2029 | |
Thereafter | |
Total future amortization for definite-lived intangible assets | $ |
66 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
December 28, 2024 | December 30, 2023 | ||
Outstanding borrowings | $ | $ | |
Outstanding letters of credit | $ | $ | |
Additional borrowing capacity | $ | $ | |
Weighted-average interest rate |
67 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Operating lease costs(1) | $ | $ | $ | ||
Variable lease costs | $ | $ | $ |
2025 | $ |
2026 | |
2027 | |
2028 | |
2029 | |
Thereafter | |
Total operating lease payments(2) | |
Less: Interest | |
Present value of operating lease liabilities | $ |
December 28, 2024 | December 30, 2023 | |||
Weighted-average remaining lease term (years) | ||||
Weighted-average discount rate |
(in thousands) | 2024 | 2023 | 2022 | |||
Cash paid for amounts included in present value of operating lease liabilities | $ | $ | $ | |||
Right-of-use assets obtained in exchange for operating lease liabilities | $ | $ | $ |
68 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Stock awards(1) | $ | $ | $ | ||
Stock options | |||||
Total stock-based compensation expense(1) | |||||
Income tax benefit | |||||
Total stock-based compensation expense, net of tax | $ | $ | $ |
Stock Options | Weighted- Average Exercise Price per Share | Weighted- Average Remaining Contractual Term (years) | Aggregate Intrinsic Value(1) | ||||
Outstanding at December 30, 2023 | $ | $ | |||||
Granted | |||||||
Exercised | |||||||
Canceled/Forfeited | ( | ||||||
Outstanding at December 28, 2024 | $ | $ | |||||
Exercisable at December 28, 2024 | $ | $ | |||||
Vested and expected to vest at December 28, 2024 | $ | $ |
2024 | 2023 | 2022 | |||
Weighted-average grant date fair value of stock options granted | $ | $ | $ | ||
Total intrinsic value (at exercise) of stock options exercised | $ | $ | $ |
69 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Valuation Assumptions | 2024 | 2023 | 2022 | ||
Expected dividend yield | |||||
Expected volatility | |||||
Risk-free interest rate | |||||
Expected term (years) | — |
Time- Based Stock Awards | Weighted- Average Grant Date Fair Value | Performance- Based Stock Awards | Weighted- Average Grant Date Fair Value | ||||
Outstanding at December 30, 2023 | $ | $ | |||||
Granted | |||||||
Vested | ( | ( | |||||
Canceled/Forfeited | ( | ( | |||||
Outstanding at December 28, 2024 | $ | $ |
2024 | 2023 | 2022 | |||
Amount repurchased under Board-approved share repurchase program | $ | $ | $ | ||
Amount repurchased in connection with the vesting of employee restricted stock grants | |||||
Total amount repurchased (based on trade dates) | $ | $ | $ |
70 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Net (loss) income | $( | $( | $ | ||
Reconciliation of weighted-average shares outstanding: | |||||
Basic weighted-average shares outstanding | |||||
Dilutive effect of stock-based awards | |||||
Diluted weighted-average shares outstanding | |||||
Net (loss) income per share – basic | $( | $( | $ | ||
Net (loss) income per share – diluted | $( | $( | $ |
December 28, 2024 | December 30, 2023 | ||
Deferred contract assets included in: | |||
Other current assets | $ | $ | |
Other non-current assets | |||
$ | $ |
December 28, 2024 | December 30, 2023 | ||
Deferred contract liabilities included in: | |||
Other current liabilities | $ | $ | |
Other non-current liabilities | |||
$ | $ |
71 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Retail stores | $ | $ | $ | ||
Online, phone, chat and other | |||||
Total Company | $ | $ | $ |
2024 | 2023 | ||
Balance at beginning of year | $ | $ | |
Additions that reduce net sales | |||
Deduction from reserves | ( | ( | |
Balance at end of period | $ | $ |
2024 | 2023 | ||||
Cash restructuring costs: | |||||
Contract termination costs(1) | $ | $ | |||
Severance and employee-related benefits | |||||
Professional fees and other | |||||
Total cash restructuring costs | |||||
Non-cash restructuring costs: | |||||
Asset impairments(2) | |||||
Total restructuring costs | $ | $ |
72 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | ||||
Balance at December 30, 2023 | $ | $ | |||
Expenses | |||||
Cash payments | ( | ( | |||
Balance at December 28, 2024 | $ | $ |
Cumulative | ||||
December 28, 2024 | ||||
Cash restructuring costs: | ||||
Contract termination costs (1) | $ | |||
Severance and employee-related benefits | ||||
Professional fees and other | ||||
Total cash restructuring costs | ||||
Non-cash restructuring costs: | ||||
Asset impairments (2) | ||||
Total restructuring costs | $ |
2024 | 2023 | 2022 | |||
Current: | |||||
Federal | $ | $ | $ | ||
State | |||||
Deferred: | |||||
Federal | ( | ( | ( | ||
State | ( | ( | ( | ||
( | ( | ( | |||
Income tax (benefit) expense | $( | $( | $ |
73 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Statutory federal income tax | |||||
State income taxes, net of federal benefit | ( | ||||
R&D tax credits | ( | ||||
Return to provision | |||||
Investment tax credit | |||||
Stock-based compensation | ( | ( | ( | ||
Non-deductible compensation | ( | ( | |||
Non-deductible expenses | ( | ( | |||
Changes in unrecognized tax benefits | ( | ( | ( | ||
Valuation allowance | ( | ||||
Other | ( | ||||
Effective income tax rate |
2024 | 2023 | ||
Deferred tax assets: | |||
Stock-based compensation | $ | $ | |
Operating lease liabilities | |||
Warranty and returns liabilities | |||
Net operating loss carryforwards and credits | |||
Compensation and benefits | |||
Research and development | |||
Interest | |||
Other | |||
Total gross deferred tax assets | |||
Valuation allowance | ( | ( | |
Total gross deferred tax assets after valuation allowance | |||
Deferred tax liabilities: | |||
Property and equipment | |||
Operating lease right-of-use assets | |||
Deferred revenue | |||
Other | |||
Total gross deferred tax liabilities | |||
Net deferred tax assets | $ | $ |
74 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Federal and State Tax | |||||
2024 | 2023 | 2022 | |||
Beginning balance | $ | $ | $ | ||
Increases related to current-year tax positions | |||||
Increases related to prior-year tax positions | |||||
Decreases related to prior-year tax positions | ( | ( | |||
Lapse of statute of limitations | ( | ( | ( | ||
Settlements with taxing authorities | ( | ||||
Ending balance | $ | $ | $ |
75 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
2024 | 2023 | 2022 | |||
Net Sales | $ | $ | $ | ||
Less: | |||||
Cost of sales | ( | ( | ( | ||
Marketing expenses | ( | ( | ( | ||
Selling expenses | ( | ( | ( | ||
General and administrative | ( | ( | ( | ||
Research and development | ( | ( | ( | ||
Restructuring costs | ( | ( | |||
Asset impairment charges | ( | ( | |||
Interest expense | ( | ( | ( | ||
Income tax benefit (expense) | ( | ||||
Net (loss) income | $( | $( | $ |
76 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
77 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
78 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
79 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
80 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Exhibit No. | Description | ||
3.1 | |||
3.2 | |||
3.3 | |||
3.4 | |||
3.5 | |||
4.1 | |||
10.1 | |||
10.2 | |||
10.3 | |||
10.4 | |||
10.5 | |||
10.6 | |||
10.7 | |||
10.8* |
81 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Exhibit No. | Description | ||
10.9† | |||
10.10† | |||
10.11† | |||
10.12† | |||
10.13† | |||
10.14† | |||
10.15† | |||
10.16† | |||
10.17† | |||
10.18† | |||
10.19† | |||
10.20† | |||
10.21 | |||
10.22 |
82 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Exhibit No. | Description | ||
10.23 | |||
10.24 | |||
10.25 | |||
10.26 | |||
10.27 | |||
10.28 | |||
10.29* | |||
10.30† | |||
10.31† | |||
10.32† | |||
10.33† | |||
10.34† | |||
10.35† | |||
10.36† |
83 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Exhibit No. | Description | ||
10.37† | |||
10.38† | |||
10.39† | |||
10.40† | |||
10.41† | |||
10.42†* | |||
10.43†* | |||
10.44† | |||
10.45† | |||
10.46† | |||
10.47† | |||
19.1* | |||
21.1* | |||
23.1* | |||
24.1* | |||
31.1* | |||
31.2* | |||
32.1* | |||
32.2* | |||
97.1† |
84 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Exhibit No. | Description | ||
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | ||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | ||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | ||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||
104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
85 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
SLEEP NUMBER CORPORATION | |||
(Registrant) | |||
March 7, 2025 | By: | /s/ Shelly R. Ibach | |
Shelly R. Ibach | |||
Chief Executive Officer | |||
(principal executive officer) | |||
By: | /s/ Francis K. Lee | ||
Francis K. Lee | |||
Chief Financial Officer | |||
(principal financial officer) | |||
By: | /s/ Joel J. Laing | ||
Joel J. Laing | |||
Chief Accounting Officer | |||
(principal accounting officer) |
86 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Name | Title | Date | ||
/s/ Shelly R. Ibach | Chair of the Board | March 7, 2025 | ||
Shelly R. Ibach | ||||
/s/ Phillip M. Eyler | Director | March 6, 2025 | ||
Phillip M. Eyler | ||||
/s/ Stephen L. Gulis, Jr. | Director | March 4, 2025 | ||
Stephen L. Gulis, Jr. | ||||
/s/ Michael J. Harrison | Director | March 4, 2025 | ||
Michael J. Harrison | ||||
/s/ Julie M. Howard | Director | March 5, 2025 | ||
Julie M. Howard | ||||
/s/ Deborah L. Kilpatrick | Director | March 3, 2025 | ||
Deborah L. Kilpatrick | ||||
/s/ Brenda J. Lauderback | Director | March 6, 2025 | ||
Brenda J. Lauderback | ||||
/s/ Stephen E. Macadam | Director | March 4, 2025 | ||
Stephen E. Macadam | ||||
/s/ Barbara R. Matas | Director | March 4, 2025 | ||
Barbara R. Matas | ||||
/s/ Angel L. Mendez | Director | March 4, 2025 | ||
Angel L. Mendez | ||||
/s/Hilary A. Schneider | Director | March 3, 2025 | ||
Hilary A. Schneider |
87 | 2024 FORM 10-K | SLEEP NUMBER CORPORATION |
Description | 2024 | 2023 | 2022 | |||
Allowances for credit losses | ||||||
Balance at beginning of period | $ | $ | $ | |||
Additions charged to costs and expenses | ||||||
Deductions from reserves | ( | ( | ( | |||
Balance at end of period | $ | $ | $ |